LFG
CPRX

Larson Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Larson Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.3K Sell
1,856
-5
-0.3% -$148 ﹤0.01% 1454
2026
Q1 		$46.1K Buy
1,861
+14
+0.8% +$334 ﹤0.01% 1403
2025
Q4 		$43.1K Buy
1,847
+1,564
+553% +$34.8K ﹤0.01% 1305
2025
Q3 		$5.58K Buy
283
+158
+126% +$3.25K ﹤0.01% 2317
2025
Q2 		$2.71K Buy
125
+114
+1,036% +$2.69K ﹤0.01% 2308
2025
Q1 		$267 Sell
11
-2,340
-100% -$52.7K ﹤0.01% 2728
2024
Q4 		$49.1K Sell
2,351
-654
-22% -$14.1K ﹤0.01% 909
2024
Q3 		$59.7K Buy
3,005
+2,994
+27,218% +$55.5K ﹤0.01% 854
2024
Q2 		$170 Buy
+11
New +$171 ﹤0.01% 2115
2023
Q2 		– Sell
-1
Closed -$17 – 1579
2023
Q1 		$17 Hold
1
– – ﹤0.01% 1530
2022
Q4 		$19 Buy
+1
New +$15 ﹤0.01% 1488

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Larson Financial Group's CPRX Position: Q2 2026 in Review

Larson Financial Group reduced its Catalyst Pharmaceutical (CPRX) stake by 0.27% in Q2 2026, selling an estimated $148 and leaving 1,856 shares worth $58.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1454.

Larson Financial Group first reported a position in CPRX in Q4 2022 and has held it in 11 quarters since. The position peaked at $59.7K in Q3 2024. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Larson Financial Group held 1,856 shares of Catalyst Pharmaceutical worth $58.3K as of Q2 2026.
  • Larson Financial Group sold 5 Catalyst Pharmaceutical shares in Q2 2026, an estimated $148.
  • Catalyst Pharmaceutical made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1454 holding.
  • Larson Financial Group first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 11 quarters since.
  • Larson Financial Group's Catalyst Pharmaceutical position peaked at $59.7K in Q3 2024.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.